Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
Add more filters










Publication year range
1.
Cancer Cell Int ; 23(1): 307, 2023 Dec 02.
Article in English | MEDLINE | ID: mdl-38042769

ABSTRACT

The HAND2-AS1 (HAND2 Antisense RNA 1) Long noncoding RNA (lncRNA) has emerged as a participant in the initiation of various cancer types, underscoring its pivotal involvement in both oncological processes and immune responses. To gain deeper insights into the functional nuances of HAND2-AS1 and identify novel avenues for cancer immunotherapy, a comprehensive evaluation of this gene was undertaken. Here, based on the co-expression network analysis and construction of interacting lncRNA-mRNA genes, we introduce the HAND2-AS1 lncRNA, emphasizing its key roles in tumorigenesis and immune regulation. Our study spans across 33 distinct cancer types, revealing the HAND2-AS1's aberrant expression patterns, methylation variations, mutational signatures, and immune engagement. Across a majority of tumors, HAND2-AS1 exhibited a propensity for down-regulation, remarkably an association with poor survival outcomes. The outcomes of functional enrichment analyses strongly suggest HAND2-AS1's engagement in tumor progression and its association with various immune pathways across diverse tumor classifications. Additionally, a positive correlation emerged between HAND2-AS1 expression and the infiltration levels of key immune cells, encompassing not only immunosuppressive entities such as tumor-associated macrophages, cancer-associated fibroblasts, and Tregs, but also immune effector cells like NK cells and CD8+ T cells, spanning a pan-cancer context. Furthermore, the differential expression of HAND2-AS1 appears to have downstream consequences on various pathways, thus implicating it as a potential regulator in diverse cancer types. Finally, we have employed CRC tumor and normal samples to carry out clinical validation of HAND2-AS1. Our study unveils HAND2-AS1's potential as a pan-cancer tumor suppressor, and its essential role in the tumorigenesis and immune surveillance. The increased HAND2-AS1 expression emerges as a promising candidate for prognostic evaluation, therapeutic strategy, and a focal point for immunotherapeutic interventions.

2.
Asian Pac J Cancer Prev ; 24(6): 1993-2001, 2023 Jun 01.
Article in English | MEDLINE | ID: mdl-37378929

ABSTRACT

OBJECTIVE: This study aimed to find the key genes and miRNAs as potential biomarkers related to the progression of colorectal cancer (CRC) from Crohn's disease (CD). BACKGROUND: CD is widely accepted as one of the main risk factors leading to CRC. So, Identifying the novel molecular pathways involved in the development of CRC from CD can provide potential solutions for therapeutic interventions. METHODS: By implementing a systematic approach, we have analyzed mRNA and miRNA datasets containing CRC and CD samples to determine differentially expressed genes (DEGs) and miRNAs (DEmiRNA). Then by selecting common genes involved in the progression from CD to CRC, different downstream analyses including mRNA-miRNA network, functional enrichment analysis, gene set enrichment analysis, and survival analysis were performed. Finally, quantitative real-time PCR (RT-PCR) analysis of tissue samples obtained from Normal/CRC samples was used to confirm the differential expression of selected genes and miRNA. RESULTS: There were 10 DE miRNA and 181 genes DEGs common between progression from CD to CRC. The genes obtained for each of the 10 miRNAs were considered as the final target for downstream analyzes. In addition, analysis of RT-PCR indicated that miR-195-5p, PHLPP2, and LITAF   were downregulated in the cancer group compared to the control group. CONCLUSION: This study showed that PHLPP2, LITAF, and miR-195-5p may have key roles in the tumorigenesis of CRC and they can be used as therapeutic targets and diagnostic biomarkers after further in-vitro and in-vivo evaluation.


Subject(s)
Colorectal Neoplasms , Crohn Disease , MicroRNAs , Humans , Systems Biology , Crohn Disease/genetics , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Gene Expression Profiling , Colorectal Neoplasms/diagnosis , MicroRNAs/genetics , MicroRNAs/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Gene Expression Regulation, Neoplastic , Gene Regulatory Networks , Phosphoprotein Phosphatases/genetics , Phosphoprotein Phosphatases/metabolism
3.
BMC Cancer ; 22(1): 835, 2022 Jul 30.
Article in English | MEDLINE | ID: mdl-35907803

ABSTRACT

BACKGROUND: A deep understanding of potential molecular biomarkers and therapeutic targets related to the progression of colorectal cancer (CRC) from early stages to metastasis remain mostly undone. Moreover, the regulation and crosstalk among different cancer-driving molecules including messenger RNAs (mRNAs), long non-coding RNAs (lncRNAs) and micro-RNAs (miRNAs) in the transition from stage I to stage IV remain to be clarified, which is the aim of this study. METHODS: We carried out two separate differential expression analyses for two different sets of samples (stage-specific samples and tumor/normal samples). Then, by the means of robust dataset analysis we identified distinct lists of differently expressed genes (DEGs) for Robust Rank Aggregation (RRA) and weighted gene co-expression network analysis (WGCNA). Then, comprehensive computational systems biology analyses including mRNA-miRNA-lncRNA regulatory network, survival analysis and machine learning algorithms were also employed to achieve the aim of this study. Finally, we used clinical samples to carry out validation of a potential and novel target in CRC. RESULTS: We have identified the most significant stage-specific DEGs by combining distinct results from RRA and WGCNA. After finding stage-specific DEGs, a total number of 37 DEGs were identified to be conserved across all stages of CRC (conserved DEGs). We also found DE-miRNAs and DE-lncRNAs highly associated to these conserved DEGs. Our systems biology approach led to the identification of several potential therapeutic targets, predictive and prognostic biomarkers, of which lncRNA LINC00974 shown as an important and novel biomarker. CONCLUSIONS: Findings of the present study provide new insight into CRC pathogenesis across all stages, and suggests future assessment of the functional role of lncRNA LINC00974 in the development of CRC.


Subject(s)
Colorectal Neoplasms , MicroRNAs , RNA, Long Noncoding , Biomarkers/metabolism , Biomarkers, Tumor/genetics , Colorectal Neoplasms/genetics , Colorectal Neoplasms/pathology , Gene Expression Profiling/methods , Gene Expression Regulation, Neoplastic , Gene Regulatory Networks , Humans , MicroRNAs/genetics , MicroRNAs/metabolism , Prognosis , RNA, Long Noncoding/genetics , RNA, Long Noncoding/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism
4.
Curr Stem Cell Res Ther ; 17(5): 400-406, 2022.
Article in English | MEDLINE | ID: mdl-35176990

ABSTRACT

Chimeric antigen receptor (CAR) T-cell therapy is a type of sophisticated tailored immunotherapy used to treat a variety of tumors. Immunotherapy works by utilizing the body's own immune system to discover and destroy malignant cells. In CAR-T therapy, a patient's own immune cells are genetically engineered to recognize and attack cancer. Treatments employing CAR T-cells are currently showing promising therapeutic results in patients with hematologic malignancies, and their safety and feasibility in solid tumors have been verified. In this review, we will discuss in detail the likelihood that CAR Tcells inhibit cancer stem cells (CSCs) by selectively targeting their cell surface markers will ultimately improve the therapeutic response for patients with various forms of cancer. This review addresses the major components of cancer stem cell (CSC)-targeted CAR T-cells against malignancies, from bench to bedside.


Subject(s)
Immunotherapy, Adoptive , Neoplasms , Humans , Immunotherapy , Immunotherapy, Adoptive/methods , Neoplasms/pathology , Neoplastic Stem Cells/pathology , Receptors, Antigen, T-Cell/genetics , T-Lymphocytes
5.
Adv Sci (Weinh) ; 9(2): e2102678, 2022 01.
Article in English | MEDLINE | ID: mdl-34796680

ABSTRACT

Cancer is one of the top life-threatening dangers to the human survival, accounting for over 10 million deaths per year. Bioactive glasses have developed dramatically since their discovery 50 years ago, with applications that include therapeutics as well as diagnostics. A new system within the bioactive glass family, mesoporous bioactive glasses (MBGs), has evolved into a multifunctional platform, thanks to MBGs easy-to-functionalize nature and tailorable textural properties-surface area, pore size, and pore volume. Although MBGs have yet to meet their potential in tumor treatment and imaging in practice, recently research has shed light on the distinguished MBGs capabilities as promising theranostic systems for cancer imaging and therapy. This review presents research progress in the field of MBG applications in cancer diagnosis and therapy, including synthesis of MBGs, mechanistic overview of MBGs application in tumor diagnosis and drug monitoring, applications of MBGs in cancer therapy ( particularly, targeted delivery and stimuli-responsive nanoplatforms), and immunological profile of MBG-based nanodevices in reference to the development of novel cancer therapeutics.


Subject(s)
Glass/chemistry , Neoplasms/diagnosis , Neoplasms/therapy , Animals , Disease Models, Animal , Hyperthermia, Induced/methods , Mice , Nanomedicine/methods , Neoplasms/immunology , Photochemotherapy/methods , Photothermal Therapy/methods , Porosity
6.
Future Virol ; 2021 Nov.
Article in English | MEDLINE | ID: mdl-34858516

ABSTRACT

This article provides a brief overview of DNA vaccines. First, the basic DNA vaccine design strategies are described, then specific issues related to the industrial production of DNA vaccines are discussed, including the production and purification of DNA products such as plasmid DNA, minicircle DNA, minimalistic, immunologically defined gene expression (MIDGE) and Doggybone™. The use of adjuvants to enhance the immunogenicity of DNA vaccines is then discussed. In addition, different delivery routes and several physical and chemical methods to increase the efficacy of DNA delivery into cells are explained. Recent preclinical and clinical trials of DNA vaccines for COVID-19 are then summarized. Lastly, the advantages and obstacles of DNA vaccines are discussed.

7.
Future Oncol ; 17(24): 3253-3270, 2021 Aug.
Article in English | MEDLINE | ID: mdl-34156258

ABSTRACT

Immunotherapy is becoming as a major treatment modality for multiple types of solid tumors, including subsets of colorectal cancers (CRCs). The successes with immunotherapy alone has largely been achieved in patients with advanced-stage mismatch-repair-deficient and microsatellite instability-high (dMMR-MSI-H) CRCs. However, the benefits of immunotherapy have not been demonstrated to be effective in patients with proficient mismatch repair (pMMR) CRC, who are microsatellite-stable (MSS) or have low levels of microsatellite instability (MSI-L). Here, we provide a comprehensive review on the immune microenvironment of CRC tumors and describe the rapid pace of scientific changes. We discuss the tremendous promise of cell-based immunotherapy strategies that are under preclinical studies/clinical trials or being used in therapeutic paradigms.


Subject(s)
Colorectal Neoplasms/therapy , Immunotherapy, Adoptive/methods , Animals , Humans , Receptors, Chimeric Antigen , Tumor Microenvironment/immunology
8.
Biotechnol Appl Biochem ; 68(2): 279-287, 2021 Apr.
Article in English | MEDLINE | ID: mdl-32275078

ABSTRACT

Sphingosine kinases type 1 (SphK1) is a key enzyme in the phosphorylation of sphingosine to sphingosine 1-phosphate (S1P). Different abnormalities in SphK1 functions may correspond with poor prognosis in various cancers. Additionally, upregulated SphK1/S1P could promote cancer cell proliferation, angiogenesis, mobility, invasion, and metastasis. MicroRNAs as conserved small noncoding RNAs play major roles in cancer initiation, progression, metastasis, etc. Their posttranscriptionally mechanisms could affect the development of cancer growth or tumorigenesis suppression. The growing number of studies has described that various microRNAs can be regulated by SphK1, and its expression level can also be regulated by microRNAs. In this review, the relationship of SphK1 and microRNA functions and their interaction in human malignancies have been discussed. Based on them novel treatment strategies can be introduced.


Subject(s)
Lysophospholipids/metabolism , MicroRNAs/metabolism , Neoplasm Proteins/metabolism , Neoplasms/metabolism , Neovascularization, Pathologic/metabolism , Phosphotransferases (Alcohol Group Acceptor)/metabolism , RNA, Neoplasm/metabolism , Sphingosine/analogs & derivatives , Humans , Neoplasms/blood supply , Neoplasms/pathology , Sphingosine/metabolism
9.
Curr Stem Cell Res Ther ; 16(3): 323-353, 2021.
Article in English | MEDLINE | ID: mdl-32928093

ABSTRACT

Mesenchymal Stem Cells (MSCs) are one of the most promising tools for cell therapy, that are isolated from bone marrow and many other adult tissues such as liver, cord blood, placenta, dental pulp and adipose tissue. Due to the lack of MHC class II expression on the surface of MSCs, they can also be used as a potent cell source for tissue regeneration in non-autologous cell therapy applications. Many advantages of MSCs such as their self-renewal, in vitro proliferation, rapid cell doubling capacity, anti-fibrotic, anti-apoptotic, anti-inflammatory, immunomodulatory and immunosuppressive effects, and also paracrine nature have been demonstrated in various pre-- clinical studies and clinical evidence. The ability of MSCs to differentiate into multiple cell lineages, as well as the lack of ethical issues in comparison with embryonic and induced Pluripotent Stem Cells (iPSCs), has introduced them as a suitable candidate for cell therapy. This review provides a comprehensive overview of various clinical trials based on MSCs for the treatment of a variety of diseases, demonstrating their capability in the treatment of dermatological, musculoskeletal, neurological, cardiovascular, respiratory, renal, gastroenterological and urological conditions, etc.


Subject(s)
Mesenchymal Stem Cell Transplantation , Mesenchymal Stem Cells , Cell Differentiation , Cell Lineage , Cell- and Tissue-Based Therapy , Humans , Immunomodulation
10.
Biotechnol Appl Biochem ; 68(6): 1313-1322, 2021 Dec.
Article in English | MEDLINE | ID: mdl-33086431

ABSTRACT

B-cell-specific Moloney leukemia virus insertion site 1 (BMI-1) is one of the stemness markers. The prognostic and clinicopathological effects of BMI-1 expression in colorectal cancer (CRC) have been in dispute with different studies. Eligible studies were retrieved from international databases up to December 2019. Studies with a relationship between the clinicopathological and prognostic value of CRC patients with BMI-1 expression were selected. The correlations in the random-effect model were evaluated using the hazard ratios, odds ratio, and 95% confidence intervals (CIs). A total of nine studies comprising Asian cases (seven studies) and European cases (two studies) covering 1,294 samples of CRC were included for this meta-analysis. The analysis suggested that in Asian cases, increased expression of BMI-1 was associated with poor overall survival (OS) and death-free survival, whereas in European populations, high expression of BMI-1 was associated with better OS. Also, overexpression of BMI-1 in the Asian population was associated with the tumor size, distant metastasis, and patient's gender and age. Results suggested that high expression of BMI-1 can be involved in the progression and invasion of CRC, and so its inhibitor-based therapies could be used to prevent the progression of CRC.


Subject(s)
Colorectal Neoplasms/diagnosis , Polycomb Repressive Complex 1/genetics , Colorectal Neoplasms/genetics , Humans , Prognosis
11.
Int Immunopharmacol ; 88: 106944, 2020 Nov.
Article in English | MEDLINE | ID: mdl-33182032

ABSTRACT

Cancer vaccines are usually derived from the patient's tumor cells or the antigens found on their surface, which may help the immune system to identify and kill these malignant cells. Current focus of many researches is designing vaccines with the hope of triggering the immune system to attack cancer cells in a more effective, reliable and safe manner. Although colorectal cancer (CRC) is recognized as the third leading cause of death by cancer, but significant advances in therapy strategies have been made in recent years, including cancer vaccine. In this review, we present various vaccine platforms that have been used in the border battle against CRC, some of which have been approved for clinical use and some are in late-stage clinical trials. Until September 2020 there is approximately 1940 clinical trials of cancer vaccines on patients with different cancer types, and also many more trials are in the planning stages, which makes it the most important period of therapeutic cancer vaccines studies in the history of the immunotherapy. In cancer vaccines clinical trials, there are several considerations that must be taken into account including engineering of antigen-presenting cells, potential toxicity of antigenic areas, pharmacokinetics and pharmacodynamics of vaccines, and monitoring of the patients' immune response. Therefore, the need to overcome immunosuppression mechanisms/immune tolerance is a critical step for the success of introducing therapeutic vaccines into the widely used drugs on market. In this way, better understanding of neoantigens, tumor immune surveillance escape mechanisms and host-tumor interactions are required to develop more effective and safe cancer vaccines.


Subject(s)
Cancer Vaccines/therapeutic use , Colorectal Neoplasms/therapy , Animals , Antigens, Neoplasm/immunology , Combined Modality Therapy , Humans
12.
Immunotherapy ; 12(17): 1269-1286, 2020 12.
Article in English | MEDLINE | ID: mdl-33019839

ABSTRACT

Antibody-based targeted therapies have been able to target cancers with enhanced specificity and high efficacy. In this regard, identifying cancer markers (antigens) that are only present (tumor-specific antigens) or have an increased expression (tumor-associated antigen) on the surface of cancer cells is a crucial step for targeted cancer treatment. Various cancer antigens have already been used for therapeutic and diagnostic purposes. MUC1 is one of the most important tumor markers with high levels of expression in various solid tumors which makes it as a potential target for antibody-based therapies. This review discusses preclinical and clinical results from various platforms based on monoclonal antibodies, nanobodies as well as bispecific antibodies against MUC1. We also highlight unmet challenges that must be overcome to generate more effective cancer immunotherapy strategies.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Immunotherapy/methods , Mucin-1/immunology , Neoplasms/immunology , Neoplasms/therapy , Antibodies, Monoclonal/immunology , Humans
13.
Curr Stem Cell Res Ther ; 15(4): 362-378, 2020.
Article in English | MEDLINE | ID: mdl-32053079

ABSTRACT

Aging is considered as inevitable changes at different levels of genome, cell, and organism. From the accumulation of DNA damages to imperfect protein homeostasis, altered cellular communication and exhaustion of stem cells, aging is a major risk factor for many prevalent diseases, such as cancer, cardiovascular disease, pulmonary disease, diabetes, and neurological disorders. The cells are dynamic systems, which, through a cycle of processes such as replication, growth, and death, could replenish the bodies' organs and tissues, keeping an entire organism in optimal working order. In many different tissues, adult stem cells are behind these processes, replenishing dying cells to maintain normal tissue function and regenerating injured tissues. Therefore, adult stem cells play a vital role in preventing the aging of organs and tissues, and can delay aging. However, during aging, these cells also undergo some detrimental changes such as alterations in the microenvironment, a decline in the regenerative capacity, and loss of function. This review aimed to discuss age-related changes of stem cells in different tissues and cells, including skin, muscles, brain, heart, hair follicles, liver, and lung.


Subject(s)
Adult Stem Cells/cytology , Cellular Senescence/physiology , Longevity/physiology , Stem Cells/cytology , Animals , Cellular Senescence/genetics , Humans , Regeneration/physiology
14.
J Biochem Mol Toxicol ; 33(12): e22410, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31617649

ABSTRACT

Multiple sclerosis (MS) is an autoimmune disease in which the immune system attacks the nerve cells, resulting in neurological disorders. Oxidative stress, free radicals, and neuritis have important roles in MS pathogenesis. Here, we aim to evaluate the effect of crocin on inflammatory markers, oxidative damage, and deoxyribonucleic acid (DNA) damage in the blood of patients with MS. A total of 40 patients were divided into two groups, drug and placebo-treated groups, using random assignment. Participants of the intervention and control groups received two crocin capsules or placebo per day for 28 days, respectively. Findings revealed a significant decrease in the level of important pathogenic factors in MS, including lipid peroxidation, DNA damage, tumor necrosis factor-alpha, and interleukin 17 as well as a significant increase in the total antioxidant capacity in the serum of patients treated with crocin compared with the placebo group. Our results suggest the beneficial and therapeutic effects of crocin in MS.


Subject(s)
Antioxidants/therapeutic use , Carotenoids/therapeutic use , DNA Damage/drug effects , Inflammation/drug therapy , Multiple Sclerosis/drug therapy , Oxidative Stress/drug effects , Plant Extracts/therapeutic use , Adult , Antioxidants/administration & dosage , Biomarkers/blood , Carotenoids/administration & dosage , Crocus/chemistry , Double-Blind Method , Female , Humans , Interleukin-17/blood , Lipid Peroxidation/drug effects , Male , Multiple Sclerosis/blood , Plant Extracts/administration & dosage , Tumor Necrosis Factor-alpha/blood , Young Adult
15.
Immunotherapy ; 11(9): 795-800, 2019 06.
Article in English | MEDLINE | ID: mdl-31094256

ABSTRACT

Utilizing immunotherapy as a potential therapeutic approach to boost the body's immune system for the fight against various diseases such as cancers, autoimmune diseases and also infections, is increasing day by day. Monoclonal antibodies, as effective therapeutic agents are used in cancer targeted therapies. However, these biologics have some disadvantages such as high costs and side effects. Therefore, emerging alternative immunotherapy strategies with high efficiency and low costs seems necessary. Mimotope vaccines, as epitope-mimicking structures, have shown to be effective therapeutic options, but are they really a good alternative to monoclonal antibodies, or are they just effective adjuvants?


Subject(s)
Antibodies, Monoclonal/therapeutic use , Autoimmune Diseases/therapy , Biomimetic Materials/therapeutic use , Cancer Vaccines/therapeutic use , Epitopes/immunology , Neoplasms/therapy , Adjuvants, Immunologic/therapeutic use , Animals , Antibodies, Monoclonal/immunology , Autoimmune Diseases/immunology , Autoimmune Diseases/pathology , Cancer Vaccines/immunology , Clinical Trials as Topic , Humans , Immune System/drug effects , Immune System/immunology , Immunotherapy/methods , Neoplasms/immunology , Neoplasms/pathology , Outcome Assessment, Health Care , Vaccination/methods
16.
Life Sci ; 228: 221-227, 2019 Jul 01.
Article in English | MEDLINE | ID: mdl-31075231

ABSTRACT

AIMS: MicroRNAs (miRNAs) are small noncoding RNAs that negatively control gene expression at the translational level. There are compelling evidences indicating that the expression of let-7e is downregulated in various cancers, however, the role of let-7e in colorectal cancer (CRC) and its mechanism has been remained unknown. Here, we investigated the potential role of let-7e in regulating CRC cells phenotypes. MAIN METHODS: Let-7e and DCLK1 siRNA were transfected in HCT-116 cells. Colony formation assay, scratch test, Annexin V/PI flow cytometry, and sphere formation assay were performed to examine the cell proliferation, migration, apoptosis, and stemness, respectively. The expression of let-7e, epithelial-mesenchymal transition (EMT)-related genes, Doublecortin like kinase protein 1 (DCLK1), and cancer stem cells (CSCs) were assessed using RT-qPCR while the protein level of DCLK1 was determined by western blotting. KEY FINDINGS: Overexpression of let-7e effectively inhibited cell proliferation, suppressed migration, reduced sphere formation, and precluded EMT process as well as stemness factors. Furthermore, let-7e suppressed DCLK1 expression. Additionally, we found that the expression of let-7e was negatively correlated with DCLK1 expression in CRC cells. SIGNIFICANCE: Let-7e plays an important role as tumor suppressor miRNA in CRC probably through inhibition of DCLK1 expression.


Subject(s)
Colorectal Neoplasms/genetics , Gene Expression Regulation, Neoplastic , Intracellular Signaling Peptides and Proteins/genetics , MicroRNAs/genetics , Protein Serine-Threonine Kinases/genetics , Carcinogenesis/genetics , Carcinogenesis/pathology , Cell Proliferation , Colorectal Neoplasms/pathology , Doublecortin-Like Kinases , Down-Regulation , Epithelial-Mesenchymal Transition , HCT116 Cells , Humans
17.
J Cell Physiol ; 234(2): 1313-1325, 2019 02.
Article in English | MEDLINE | ID: mdl-30191996

ABSTRACT

Recent studies show that cancer cells are sometimes able to evade the host immunity in the tumor microenvironment. Cancer cells can express high levels of immune inhibitory signaling proteins. One of the most critical checkpoint pathways in this system is a tumor-induced immune suppression (immune checkpoint) mediated by the programmed cell death protein 1 (PD-1) and its ligand, programmed death ligand 1 (PD-L1). PD-1 is highly expressed by activated T cells, B cells, dendritic cells, and natural killer cells, whereas PD-L1 is expressed on several types of tumor cells. Many studies have shown that blocking the interaction between PD-1 and PD-L1 enhances the T-cell response and mediates antitumor activity. In this review, we highlight a brief overview of the molecular and biochemical events that are regulated by the PD-1 and PD-L1 interaction in various cancers.


Subject(s)
Antineoplastic Agents, Immunological/therapeutic use , B7-H1 Antigen/antagonists & inhibitors , Immunotherapy/methods , Neoplasms/drug therapy , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Animals , Antineoplastic Agents, Immunological/adverse effects , B7-H1 Antigen/immunology , B7-H1 Antigen/metabolism , Humans , Immunotherapy/adverse effects , Molecular Targeted Therapy , Neoplasms/immunology , Neoplasms/metabolism , Neoplasms/pathology , Programmed Cell Death 1 Receptor/immunology , Programmed Cell Death 1 Receptor/metabolism , Signal Transduction , Treatment Outcome , Tumor Escape , Tumor Microenvironment
18.
J Biomol Struct Dyn ; 37(11): 2789-2800, 2019 Jul.
Article in English | MEDLINE | ID: mdl-30052136

ABSTRACT

In this study, Farnesiferol C was introduced as an anti-colon cancer agent. Its cytotoxicity was investigated on two cancer cell lines, HCT116 and CT26, and mesenchymal stem cells (MSCs) as normal cells employing MTT assay. Moreover, Farnesiferol C interactions with ct-DNA and HSA were investigated by various techniques. The IC50 values of Farnesiferol C on HCT116 and CT26 cells were 42 and 46 µM, respectively, while its IC50 value on MSCs cells was 92 µM, indicating that Farnesiferol C was more efficacious against cancer cell lines than normal cells. DNA competitive binding studies, viscosity and zeta potential measurements confirmed that Farnesiferol C bound to DNA through intercalation binding. HSA binding investigations revealed that there were two different binding sites for Far C on HSA with higher binding affinity in site 2 compared to site 1. Furthermore, Farnesiferol C could bind to HSA and quench its intrinsic fluorescence in a static quenching mechanism, with a distance of 2.54 nm. Competitive binding in the presence of warfarin and ibuprofen was carried out and the resulting quenching constant was strongly changed in the presence of warfarin. Consequently, Farnesiferol C most probably will be located within sub-domain IIA. In this study, molecular modeling buttressed and confirmed our laboratory results. Conclusively, we proposed that DNA is an appropriate target for Farnesiferol C. Therefore, Farnesiferol C and its semisynthetic analogues can be one of the priority innovations in research on anticancer drugs.


Subject(s)
Antineoplastic Agents/pharmacology , Colonic Neoplasms/drug therapy , Coumarins/pharmacology , DNA/metabolism , Ferula/chemistry , Mesenchymal Stem Cells/drug effects , Serum Albumin, Human/metabolism , Animals , Antineoplastic Agents/chemistry , Binding Sites , Binding, Competitive , Cell Proliferation , Cells, Cultured , Colonic Neoplasms/metabolism , Colonic Neoplasms/pathology , Coumarins/chemistry , DNA/chemistry , Humans , Mesenchymal Stem Cells/cytology , Mesenchymal Stem Cells/metabolism , Models, Molecular , Protein Binding , Protein Conformation , Rats , Serum Albumin, Human/chemistry , Serum Albumin, Human/drug effects
19.
Aesthetic Plast Surg ; 43(3): 803-814, 2019 06.
Article in English | MEDLINE | ID: mdl-30552470

ABSTRACT

INTRODUCTION: In recent years, platelet-rich plasma (PRP) has emerged as a promising autologous biological treatment modality for the use in aesthetic and regenerative medicine. PRP is a high concentration of platelets derived from whole blood which is isolated by centrifugation to separate and concentrate platelet-containing plasma from red blood cells. PRP comprises hundreds of bioactive proteins, including growth factors, peptides, and cytokines that stimulate healing of skin and soft tissues. Attractive features of PRP are the extended release of various growth and differentiation factors from activated platelets, tissue regenerative, and healing capabilities, as well as the lack of problems associated with immunogenicity. Because of the unique biological features of this whole blood-derived biological agent, multiple clinical uses for PRP exist for aesthetic and regenerative medicine. EVIDENCE ACQUISITIONS: A comprehensive review of the literature regarding the use of platelet-rich plasma in aesthetic and regenerative medicine was performed. EVIDENCE SYNTHESIS: Therapeutic applications of PRP including several methods for its clinical deployment in conditions related to aesthetic and regenerative medicine including wound healing, skin and facial rejuvenation, hair restoration, hand rejuvenation, breast augmentation, and musculoskeletal regeneration were reviewed. CONCLUSION: PRP treatment has shown itself as a bright future for a safe and efficient cosmetic intervention. However, more studies are needed to better our understanding of limitations and benefits in clinical phases associated with the aesthetic use of PRP. LEVEL OF EVIDENCE III: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .


Subject(s)
Cosmetic Techniques , Platelet-Rich Plasma , Regeneration , Rejuvenation , Humans
20.
J Cell Physiol ; 234(7): 10718-10725, 2019 07.
Article in English | MEDLINE | ID: mdl-30515804

ABSTRACT

Abnormal expression of various microRNAs (miRNAs), as regulators of biological signaling pathways, has a strong association with cancer resistance to chemotherapy and radiotherapy. The let-7 family of miRNAs as tumor suppressors have shown to be downregulated in different types of human malignancies including colorectal cancer (CRC). However, the biological function of let-7 members in the processes of resistance to radiation in CRC has not yet been completely elucidated. Insulin-like growth factor 1 receptor (IGF-1R) signaling pathway is amplified in CRC and leads to its progression, development, and also radiation resistance. So, it seems like an attractive target for anticancer therapy. In this study, by using bioinformatics analysis, it has been revealed that IGF-1R is a direct target of the let-7e member. Consistent with this, we identified that increased levels of let-7e in CRC cells reduced IGF-1R protein level and subsequently its downstream signaling pathways, which resulted in the G1 cell cycle arrest and a significant reduction in the proliferation, survival and also resistance to radiation of CRC cells. Altogether, these results suggested that let-7e by targeting the IGF-1R signaling pathway might serve as therapeutics in anticancer therapy.


Subject(s)
Cell Proliferation/genetics , Colorectal Neoplasms/radiotherapy , MicroRNAs/genetics , Receptor, IGF Type 1/genetics , Colorectal Neoplasms/genetics , Colorectal Neoplasms/pathology , Gene Expression Regulation, Neoplastic/radiation effects , HCT116 Cells , Humans , Radiation Tolerance/genetics , Signal Transduction/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...